ASCO in 30: Immunotherapy controversy & less is just as good – STAT
STAT |
ASCO in 30: Immunotherapy controversy & less is just as good
STAT Sharon covers science and discovery. sharon.begley@statnews.com 3. @sxbegle 4. Adam Feuerstein 5. Senior Writer, Biotech. Adam is STAT's national biotech columnist, reporting on the intersection of biotech and Wall Street. |
